RA Capital, Forbion and Sanofi Ventures back Korean eye-drug startup

RA Capital, Forbion and Sanofi Ventures are reported to be providing financing for a new eye-drug company that is developing its product in Korea.

The investment follows a growing pattern where large venture firms join forces to back emerging biotech firms that are licensing experimental medicines from other companies.

The article offers limited detail beyond the involvement of the three investors and the focus on an eye-disease therapy, reflecting a broader trend in biotech financing.